Two more pharmas practice their Accent, invest in $75M series C round
Accent Therapeutics has reeled in investments from two more pharmaceutical companies as part of a $75M series C, the latest validation for the RNA drug developer.
Accent Therapeutics has reeled in investments from two more pharmaceutical companies as part of a $75M series C, the latest validation for the RNA drug developer.
Sanofi has taken a surgical approach to its latest piece of M&A, agreeing to pay $1.7 billion to buy Inhibrx for below the market price but then spin out all but one of its candidates to create a new publicly traded biotech.
Karuna Therapeutics was almost bought out by another large pharma that competed up until the last moment before Bristol Myers Squibb’s $14 billion proposal won out.
After slimming down its product suite with the sale last year of its robotic surgery system, Accelus is doubling down on its remaining offerings.
Sagimet Biosciences has eased the pain of investors who backed its IPO last year, reporting phase 2b data in metabolic-associated steatohepatitis (MASH) that sent its stock soaring. Yet, the 20% dropout rate in the drug arm and exclusion of patients from the analysis prompted questions from analysts.
As one of the first in a new year wave of biotechs to announce IPO plans, Arrivent Biopharma has now said it expects to raise around $135 million in the company’s upcoming public offering.
Despite having an FDA-approved injectable product, pruritus-focused drug developer Cara Therapeutics is laying off up to half of its staff as it narrows its clinical ambitions.
Just a few weeks after earning a permanent injunction barring the use of Invitae’s Personalized Cancer Monitoring tests, Natera is taking another of the diagnostic developer’s product portfolios off its hands.
Dexcom has joined the scrum of major U.S.-based medtech companies flocking to Ireland as a European home base.
Novo Holdings is fattening up as patients slim down. Boosted by the Wegovy windfall, the fund manager’s CEO Kasim Kutay expects to do “a fair amount” more deals in 2024 and to open a second office in Asia.